Brokerages Set Reckitt Benckiser Group plc (OTCMKTS:RBGLY) Price Target at $5,400.00

Shares of Reckitt Benckiser Group plc (OTCMKTS:RBGLY) have been assigned a consensus recommendation of “Hold” from the seven research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $5,400.00.

Separately, JPMorgan Chase & Co. cut Reckitt Benckiser Group from an “overweight” rating to a “neutral” rating in a research note on Thursday.

Reckitt Benckiser Group Stock Up 0.3 %

Shares of RBGLY stock opened at $11.56 on Thursday. The stock has a 50-day moving average of $11.10 and a 200-day moving average of $11.57. Reckitt Benckiser Group has a one year low of $10.24 and a one year high of $15.03.

Reckitt Benckiser Group Cuts Dividend

The firm also recently declared a dividend, which will be paid on Monday, September 23rd. Stockholders of record on Monday, August 5th will be paid a dividend of $0.1915 per share. The ex-dividend date is Monday, August 5th.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.